{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:19:38Z","timestamp":1791569978006,"version":"4.3.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Chronic migraines affect approximately 2 percent of the U.S. population and cost an estimated $17 billion per year. OnabotulinumtoxinA (botulinum toxin type A) is a U.S. Food and Drug Administration\u2013approved prophylactic medication for chronic migraine headaches and is best injected in a targeted fashion into specific trigger sites. The purpose of this study was to determine the cost-effectiveness of long-term, targeted botulinum toxin type A versus peripheral trigger site deactivation surgery for the treatment of migraine headaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A Markov model was constructed to examine long-term, targeted botulinum toxin type A versus peripheral trigger site deactivation surgery. Costs, utilities, and other model inputs were identified from the literature. One-way and probabilistic sensitivity analyses were performed. An incremental cost-effectiveness ratio under $50,000 per quality-adjusted life-year was considered cost-effective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean cost of peripheral trigger site deactivation surgery was $10,303, with an effectiveness of 7.06; whereas the mean cost of long-term, targeted botulinum toxin type A was $36,071, with an effectiveness of 6.34. Trigger-site deactivation surgery is more effective and less costly over the time horizon of the model. One-way sensitivity analysis revealed that surgery is the most cost-effective treatment in patients requiring treatment for greater than 6.75 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Based on this model, peripheral trigger site deactivation surgery is the more cost-effective option for treating refractory migraine headaches requiring treatment beyond 6.75 years. The model reveals that peripheral trigger-site deactivation surgery is more effective and less costly than long-term, targeted botulinum toxin type A over the course of a patient\u2019s lifetime.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/prs.0000000000006480","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T11:34:52Z","timestamp":1576496092000},"page":"401e-406e","source":"Crossref","is-referenced-by-count":29,"title":["Cost-Effectiveness of Long-Term, Targeted OnabotulinumtoxinA versus Peripheral Trigger Site Deactivation Surgery for the Treatment of Refractory Migraine Headaches"],"prefix":"10.1097","volume":"145","author":[{"given":"Anna R.","family":"Schoenbrunner","sequence":"first","affiliation":[{"name":"From the Department of Plastic and Reconstructive Surgery, The Ohio State University; and the Section of Plastic and Reconstructive Surgery, Nationwide Children\u2019s Hospital."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khansa","sequence":"additional","affiliation":[{"name":"From the Department of Plastic and Reconstructive Surgery, The Ohio State University; and the Section of Plastic and Reconstructive Surgery, Nationwide Children\u2019s Hospital."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Janis","sequence":"additional","affiliation":[{"name":"From the Department of Plastic and Reconstructive Surgery, The Ohio State University; and the Section of Plastic and Reconstructive Surgery, Nationwide Children\u2019s Hospital."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231017","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition.","volume":"33","year":"2013","journal-title":"Cephalalgia"},{"key":"R2-20231017","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS).","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"key":"R3-20231017","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","article-title":"Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study.","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"key":"R4-20231017","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: A systematic review.","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"R5-20231017","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/head.12755","article-title":"Direct and indirect costs of chronic and episodic migraine in the United States: A Web-based survey.","volume":"56","author":"Messali","year":"2016","journal-title":"Headache"},{"issue":"Suppl","key":"R6-20231017","first-page":"S62","article-title":"The cost of migraine and its treatment.","volume":"11","author":"Goldberg","year":"2005","journal-title":"Am J Manag Care"},{"key":"R7-20231017","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/WNL.0b013e318232ab65","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.","volume":"77","author":"Lipton","year":"2011","journal-title":"Neurology"},{"key":"R8-20231017","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.","volume":"86","author":"Silberstein","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R9-20231017","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1474-4422(09)70090-0","article-title":"Origin of pain in migraine: Evidence for peripheral sensitisation.","volume":"8","author":"Olesen","year":"2009","journal-title":"Lancet Neurol"},{"key":"R10-20231017","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/toxins7083127","article-title":"Botulinum toxin for neuropathic pain: A review of the literature.","volume":"7","author":"Oh","year":"2015","journal-title":"Toxins (Basel)"},{"key":"R11-20231017","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","article-title":"Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.","volume":"120","author":"Meng","year":"2007","journal-title":"J Cell Sci"},{"key":"R12-20231017","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1464-410X.2007.07312.x","article-title":"Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.","volume":"101","author":"Lucioni","year":"2008","journal-title":"BJU Int"},{"key":"R13-20231017","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/toxins7072435","article-title":"Botulinum toxin as a pain killer: Players and actions in antinociception.","volume":"7","author":"Kim","year":"2015","journal-title":"Toxins (Basel)"},{"key":"R14-20231017","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.juro.2007.07.120","article-title":"Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat.","volume":"180","author":"Chuang","year":"2008","journal-title":"J Urol"},{"key":"R15-20231017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.toxicon.2017.05.001","article-title":"Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain.","volume":"133","author":"Fan","year":"2017","journal-title":"Toxicon"},{"key":"R16-20231017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00006534-200008000-00030","article-title":"Corrugator supercilii muscle resection and migraine headaches.","volume":"106","author":"Guyuron","year":"2000","journal-title":"Plast Reconstr Surg"},{"key":"R17-20231017","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/PRS.0000000000004795","article-title":"Surgical treatment of migraine headache: Back to the future.","volume":"142","author":"Gfrerer","year":"2018","journal-title":"Plast Reconstr Surg"},{"key":"R18-20231017","doi-asserted-by":"crossref","first-page":"564e","DOI":"10.1097\/PRS.0b013e31822b632a","article-title":"Five-year outcome of surgical treatment of migraine headaches.","volume":"128","author":"Caviggioli","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R19-20231017","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/PRS.0b013e3181fed456","article-title":"Five-year outcome of surgical treatment of migraine headaches.","volume":"127","author":"Guyuron","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R20-20231017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.PRS.0000145631.20901.84","article-title":"Comprehensive surgical treatment of migraine headaches.","volume":"115","author":"Guyuron","year":"2005","journal-title":"Plast Reconstr Surg"},{"key":"R21-20231017","doi-asserted-by":"crossref","first-page":"131S","DOI":"10.1097\/PRS.0000000000000661","article-title":"A review of current evidence in the surgical treatment of migraine headaches.","volume":"134","author":"Janis","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"R22-20231017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/PRS.0b013e3182173d64","article-title":"Validation of the peripheral trigger point theory of migraine headaches: Single-surgeon experience using botulinum toxin and surgical decompression.","volume":"128","author":"Janis","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R23-20231017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/archfaci.4.4.274","article-title":"Surgical treatment of migraine headaches.","volume":"4","author":"Matarasso","year":"2002","journal-title":"Arch Facial Plast Surg"},{"key":"R24-20231017","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/PRS.0b013e3182818b7f","article-title":"Positive botulinum toxin type a response is a prognosticator for migraine surgery success.","volume":"131","author":"Lee","year":"2013","journal-title":"Plast Reconstr Surg"},{"key":"R25-20231017","doi-asserted-by":"crossref","first-page":"e1270","DOI":"10.1097\/GOX.0000000000001270","article-title":"Targeted peripheral nerve-directed onabotulinumtoxin A injection for effective long-term therapy for migraine headache.","volume":"5","author":"Janis","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R27-20231017","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/PRS.0b013e318244217a","article-title":"A socioeconomic analysis of surgical treatment of migraine headaches.","volume":"129","author":"Faber","year":"2012","journal-title":"Plast Reconstr Surg"},{"key":"R28-20231017","doi-asserted-by":"crossref","first-page":"NP462","DOI":"10.1093\/asj\/sjz069","article-title":"Cost-utility analysis of surgical decompression relative to injection therapy for chronic migraine headaches.","volume":"39","author":"Shauly","year":"2019","journal-title":"Aesthet Surg J"},{"key":"R29-20231017","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1046\/j.1526-4610.2003.03210.x","article-title":"Single-site botulinum toxin type a injection for elimination of migraine trigger points.","volume":"43","author":"Behmand","year":"2003","journal-title":"Headache"},{"key":"R37-20231017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PRS.0000000000001322","article-title":"A prospective randomized outcomes comparison of two temple migraine trigger site deactivation techniques.","volume":"136","author":"Guyuron","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R38-20231017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/PRS.0b013e3181adcf6a","article-title":"A placebo-controlled surgical trial of the treatment of migraine headaches.","volume":"124","author":"Guyuron","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R39-20231017","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMsr1302176","article-title":"The human resources for health program in Rwanda: New partnership.","volume":"369","author":"Binagwaho","year":"2013","journal-title":"N Engl J Med"},{"key":"R40-20231017","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/PRS.0000000000002888","article-title":"Intranasal pathology in the migraine surgery population: Incidence, patterns, and predictors of surgical success.","volume":"139","author":"Lee","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"R41-20231017","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/PRS.0000000000005353","article-title":"Therapeutic role of fat injection in the treatment of recalcitrant migraine headaches.","volume":"143","author":"Guyuron","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"R42-20231017","doi-asserted-by":"crossref","first-page":"393e","DOI":"10.1097\/PRS.0000000000000862","article-title":"Intraoperative corticosteroid injections in migraine surgery: Efficacy in preventing refractory symptoms.","volume":"135","author":"Lineberry","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R43-20231017","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/SAP.0b013e3182898736","article-title":"Greater occipital nerve excision for occipital neuralgia refractory to nerve decompression.","volume":"72","author":"Ducic","year":"2014","journal-title":"Ann Plast Surg"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000006480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T13:58:50Z","timestamp":1697551130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000006480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000006480","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}